/ARTV
ARTV Stock - Artiva Biotherapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$4.74+1.94%
+$0.09 (+1.94%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+332.5%upside
Target: $20.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ARTV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.69 – $4.79
TARGET (TP)$20.50
STOP LOSS$4.36
RISK/REWARD1:41.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.13
52W High$11.55
52W Low$1.47
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $251,000 | $33.49M | $4.93M | $2.00M | N/A |
| Gross Profit | $251,000 | $33.49M | $4.93M | $2.00M | N/A |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-67,282,000 | $-30,671,000 | $-59,829,000 | $-53,272,000 | $-18,271,000 |
| Net Income | $-58,493,000 | $-27,696,000 | $-58,388,000 | $-71,825,000 | $-17,991,000 |
| Net Margin | -23304.0% | -82.7% | -1184.1% | -3587.7% | N/A |
| EPS | $-5.20 | $-1.19 | $-3.32 | $-4.08 | $-1.02 |
Company Overview
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$20
Average Target
↑ 311.4% Upside
Now
$12
Low
$20
Average
$23
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 11th 2025 | H.C. Wainwright | Resumed | Buy | $12 |
| December 30th 2024 | H.C. Wainwright | Initiation | Buy | $20 |
| August 13th 2024 | Jefferies | Initiation | Buy | $21 |
| August 13th 2024 | Cantor Fitzgerald | Initiation | Overweight | $23 |
| August 13th 2024 | TD Cowen | Initiation | Buy | - |
| August 13th 2024 | Wedbush | Initiation | Outperform | $18 |
| August 13th 2024 | Needham | Initiation | Buy | $23 |
Earnings History & Surprises
ARTVBeat Rate
33%
Last 6 quarters
Avg Surprise
-74.9%
EPS vs Estimate
Beats / Misses
2/4
Last 12 quarters
Latest EPS
$-0.88
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
-400.0%
$-22.00vs$-4.40
Q4 24
-35.3%
$-0.92vs$-0.68
Q1 25
+7.0%
$-0.66vs$-0.71
Q2 25
-22.1%
$-0.83vs$-0.68
Q3 25
-3.6%
$-0.87vs$-0.84
Q4 25
+4.3%
$-0.88vs$-0.92
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 23, 2026 | $-0.87 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.92 | $-0.88 | +4.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.84 | $-0.87 | -3.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.68 | $-0.83 | -22.1% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-0.71 | $-0.66 | +7.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.68 | $-0.92 | -35.3% | ✗ MISS |
Q3 2024 | Aug 29, 2024 | $-4.40 | $-22.00 | -400.0% | ✗ MISS |
Q2 2024 | Jun 30, 2024 | — | $-0.62 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.30 | — | — |
Q3 2023 | Sep 30, 2023 | — | $1.20 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.90 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.95 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $15
📈 PositiveBenzinga•Nov 12, 2025, 06:53 PM
Artiva Biotherapeutics Showcases AlloNK As First Off-The-Shelf NK Cell Therapy Demonstrating Deep B-Cell Depletion With Favorable Tolerability Profile
📈 PositiveBenzinga•Nov 12, 2025, 12:25 PM
Artiva Biotherapeutics Q3 EPS $(0.88), Inline
➖ NeutralBenzinga•Nov 12, 2025, 12:13 PM
Artiva Biotherapeutics To Host Event For Discussing Safety, Translational Data For AlloNK In Combination With Anti-cd20 Antibodies Across Autoimmune Diseases
➖ NeutralBenzinga•Nov 3, 2025, 09:19 PM
Artiva Biotherapeutics shares are trading higher after the company announced that the FDA granted Fast Track Designation to AlloNK. Also, Wedbush raised its price target on the stock from $18 to $23.
📈 PositiveBenzinga•Oct 17, 2025, 01:10 PM
Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $23
📈 PositiveBenzinga•Oct 17, 2025, 12:29 PM
Market-Moving News for October 17th
➖ NeutralBenzinga•Oct 17, 2025, 11:27 AM•Also: ,
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target
📈 PositiveBenzinga•Oct 17, 2025, 10:34 AM
Artiva Biotherapeutics shares are trading higher after the company announced that the FDA granted Fast Track Designation to AlloNK.
📈 PositiveBenzinga•Oct 16, 2025, 08:21 PM
Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK; Continued Execution And Enrollment Progress With More Than 20 Patients Treated With AlloNK + Monoclonal Antibody Therapy Across Company-sponsored And Investigator-Initiated Trials In Autoimmune Diseases
📈 PositiveBenzinga•Oct 16, 2025, 08:08 PM
Frequently Asked Questions about ARTV
What is ARTV's current stock price?
Artiva Biotherapeutics, Inc. (ARTV) is currently trading at $4.74 per share. The stock has moved +1.94% today.
What is the analyst price target for ARTV?
The average analyst price target for ARTV is $20.50, based on 1 analyst.
What sector is Artiva Biotherapeutics, Inc. in?
Artiva Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ARTV's market cap?
Artiva Biotherapeutics, Inc. has a market capitalization of $0.12 billion, making it a small-cap company.
Does ARTV pay dividends?
No, Artiva Biotherapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVM
Adverum Biotechnologies, Inc.
$4.36
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
DTIL
Precision BioSciences, Inc.
$4.49
Mkt Cap: $0.1B
GUTS
Fractyl Health, Inc. Common Stock
$2.20
Mkt Cap: $0.2B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to ARTV for comparison